Proprotein convertases (PC1/PC3 and PC2) in normal and neoplastic human tissues: their use as markers of neuroendocrine differentiation
The DOI matches its Crossref record.
Abstract
By immunocytochemistry and immunoblotting, we examined normal and neoplastic human tissues with polyclonal antibodies raised against selected peptide regions of proprotein convertase-2 and -3 (PC2 and PC3), two proteases that have been shown to selectively cleave neuroendocrine precursor molecules at pairs of basic residues. Immunoreactivity for both enzymes was detected in neuroendocrine cells of pituitary, gut, pancreas, thyroid, and adrenals and in tumors thereof, but was absent in thyroid follicular cells, parathyroids, adrenal cortex, testes, and a number of nonneuroendocrine tissues, both normal and tumorous. Although both PCs were virtually universal concomitants of the neuroendocrine system, cells with a neural phenotype (e.g. pheochromocytes and Merkel cells) predominantly contained PC2, whereas classic endocrine cells contained mostly PC3. PC3 immunoreactive cells were abundant all along the gastrointestinal tract, whereas PC2 was highly expressed only in the pyloric antrum and proximal third of duodenum. Double immunostaining experiments revealed colocalization of PC3 with virtually all gastrointestinal peptides, whereas PC2 immunoreactivity was mostly expressed in gastrin, cholecystokinin, and somatostatin cells. Noticeably, the proportion of glucagon-producing cells immunoreactive for PC3 was high in the gut and low in pancreatic islets and glucagonomas, whereas the reverse occurred for PC2. At the ultrastructural level, immunostaining was confined to the mature dense core granules, the site of storage of granins and peptide hormones. With the exception of parathyroid cells, PC2 and/or PC3 expression correlated with the occurrence of granins, canonical markers of the secretory granules. Immunoblotting experiments confirmed the identity of the immunocytochemical reactivities. It is concluded that PC2 and PC3 are highly sensitive markers of neuroendocrine differentiation and have distinct distribution patterns, and that antibodies to these enzymes may play an important role in the analysis of tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“Recent findings have shown that the expression level of PC2 is high in the pancreatic cells and absent in the gut, whereas PC1/3 is definitely expressed in gut endocrine cells (Rouillé et al., 1994; Scopsi et al., 1995).”
BackgroundSeidah, N. G., & Chrétien, M. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01909-5 · Cited by 761
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680
α-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2
Furuta, M., Yano, H., Zhou, A., Rouillé, Y., Holst, J. J., Carroll, R., Ravazzola, M., Orci, L., Furuta, H., & Steiner, D. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6646 · Cited by 431
Jackson, R. S., Creemers, J. W. M., Farooqi, I. S., Raffin-Sanson, M.-L., Varro, A., Dockray, G. J., Holst, J. J., Brubaker, P. L., Corvol, P., Polonsky, K. S., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18784 · Cited by 368
The Gastrins: Their Production and Biological Activities
Dockray, G. J., Varro, A., Dimaline, R., & Wang, T. (2001) · Annual Review of Physiology · doi:10.1146/annurev.physiol.63.1.119 · Cited by 347
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315
“[8] Scopsi L, Gullo M, Rilke F, et al.”
BackgroundPOMC: The Physiological Power of Hormone Processing
Harno, E., Gali Ramamoorthy, T., Coll, A. P., & White, A. (2018) · Physiological Reviews · doi:10.1152/physrev.00024.2017 · Cited by 262
Moriscot, C., de Fraipont, F., Richard, M., Marchand, M., Savatier, P., Bosco, D., Favrot, M., & Benhamou, P. (2005) · STEM CELLS · doi:10.1634/stemcells.2004-0123 · Cited by 260
Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling
Oh, Y., & Jun, H.-S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010026 · Cited by 217
“Processing of proglucagon by prohormone convertase 1/3 in the gut and brain produces GLP-1, GLP-2, oxyntomodulin, glicentin, and intervening peptide-2 [55], and GLP-1 is the major peptide generated from proglucagon in the intestine.”
BackgroundInfluentialImplication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system
Poirier, S., Prat, A., Marcinkiewicz, E., Paquin, J., Chitramuthu, B. P., Baranowski, D., Cadieux, B., Bennett, H. P. J., & Seidah, N. G. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03928.x · Cited by 121
Intra-islet glucagon-like peptide 1
Fava, G. E., Dong, E. W., & Wu, H. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.05.016 · Cited by 45
“PC1/3 expression and its role in pancreatic islets Several lines of evidence support that the prohormone convertase PC1/3 is responsible for the post-translational cleavage of GLP-1 from proglucagon in the intestinal L-cells (Dhanvantari, et al. 1996; Mineo et al. 1995; Neerman-Arbez, et al. 1994; Rothenberg et al. 19…”
BackgroundInfluentialTani, Y., Sugiyama, T., Izumiyama, H., Yoshimoto, T., Yamada, S., & Hirata, Y. (2011) · Endocrine Journal · doi:10.1507/endocrj.k10e-389 · Cited by 25
“We have previously shown that PC1/3 mRNA is more abundantly expressed than PC2 mRNA in pituitary ACTH-secreting tumors causing CD [11], and both PC1/3 and PC2 are expressed in neuroendocrine tumors (NET) including carcinoid tumors [12].”
Metadata
- Authors
- Scopsi, L.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1995-01-01
- Volume
- 80
- Issue
- 1
- Pages
- 294-301
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2097862398
- Cited by
- 141
- References
- 0
- FWCI
- 10.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.